By Fineline Cube Jenscare Scientific Co., Ltd (HKG: 9877), a structural heart disease device manufacturer, announced 12-month follow-up results from the global EU TRINITY study for its LuX-Valve Plus transjugular tricuspid valve replacement system in patients with large annuli. The data demonstrated excellent efficacy and safety, with 97.8% of patients showing no greater than moderate tricuspid regurgitation at one year.
Clinical Trial Overview
| Item | Detail |
|---|---|
| Company | Jenscare Scientific Co., Ltd (HKG: 9877) |
| Device | LuX-Valve Plus transjugular tricuspid valve replacement system |
| Study Name | EU TRINITY |
| Study Design | Global prospective, multicenter, single-arm clinical trial |
| Patient Population | Severe tricuspid regurgitation, high surgical risk, large annuli |
| Total Enrollment | 161 patients (full analysis set plus learning curve) |
| Global Centers | 20 centers across Europe (18 centers in France, Germany, Spain, Denmark, UK) |
| Follow-Up Period | 12 months |
Key Efficacy Results – Large Annuli Cohort
| Endpoint | Result |
|---|---|
| Tricuspid Regurgitation Improvement | 97.8% achieved ≤ moderate regurgitation |
| NYHA Functional Class Improvement | 91.6% improved to Class I/II |
| KCCQ Score Improvement | Mean +17 points |
| 6-Minute Walk Test Improvement | Mean +43 meters |
Clinical Significance
- Unmet Medical Need: Addresses severe tricuspid regurgitation in high-risk surgical patients with large annuli—a particularly challenging anatomical subset
- Transjugular Approach: Minimally invasive delivery via jugular vein reduces procedural complexity compared to surgical alternatives
- Functional Outcomes: Substantial improvements in quality of life (KCCQ) and exercise capacity (6-minute walk test) demonstrate meaningful clinical benefit
- Safety Profile: Favorable safety outcomes in high-risk patient population support device viability
- Global Validation: European multi-center data provides robust evidence across diverse healthcare systems
Strategic Market Positioning
The compelling 12-month data positions LuX-Valve Plus as a leading solution in the emerging transcatheter tricuspid valve replacement market, which analysts project could reach $2+ billion annually by 2030. Jenscare’s success in the challenging large annuli population addresses a critical gap in current treatment options.
Industry observers note that tricuspid valve disease has historically been undertreated due to limited therapeutic options and poor surgical outcomes, but transcatheter approaches like LuX-Valve Plus are transforming the treatment paradigm for this underserved patient population.
Commercial Implications & Global Expansion
- Regulatory Pathway: Strong European clinical data supports potential CE Mark expansion and FDA Investigational Device Exemption (IDE) applications
- Market Differentiation: Superior outcomes in large annuli patients create competitive advantage over alternative transcatheter approaches
- Revenue Growth: Positions Jenscare for accelerated adoption in European markets and potential U.S. market entry
- Technology Leadership: Establishes company as innovator in complex structural heart interventions
- Investment Attraction: Robust clinical data likely to enhance strategic partnership and financing opportunities
Forward-Looking Statements
This brief contains forward-looking statements regarding Jenscare’s clinical development program and commercial prospects. Actual results may differ due to regulatory decisions, competitive dynamics, and market adoption rates in structural heart disease therapeutics.-Fineline Info & Tech